Maysa Vilbert

Oncologist passionate about enhancing the lives of cancer survivors, advancing cancer research, and investigating immune toxicities.

[ASPIRE Community of Practice @ASPIRE_CoP]

Check out this IRAE chapter in the #ASCO25 education book! Come attend the session on May 30th details ⬇️

[ASPIRE Community of Practice @ASPIRE_CoP]

🚀 More #irAE highlights forthcoming from #ASCO25 and ASCO’s #ASPIRE Community of Practice
🆕 go-to hub for clinicians addressing immune-related toxicities!
🌟 FREE access for non-oncologists (for a limited time), expert discussion + content
https://t.co/3C2Fm3cYyr

[Ayesha Aijaz @Ayeshaaijaz]

Happening now at #ASCO25!
Come check out my poster at Board #67 in Hall A — would love to connect and discuss our findings! 🧬🩺
#oncology #cancerresearch #NSIGC #immunotherapy #irAE @ASPIRE_CoP

[Ticiana Batista (Leal) @LealTiciana]

Thank you OncoDaily! Honored to be on the ballot for the 2025 @IASLC Board of Directors and look forward to the opportunity to expand optimal lung cancer care and clinical trials on a global scale. @RamalingamMD @IASLC @WinshipAtEmory

[Afreen Shariff, MD @afreenshariffmd]

Its a wrap!
It was a pleasure to host my colleagues and friends around the country for the 2nd #ASPIRE2025 and 3rd #NICT2025 meeting

25 speakers
38 organizations
15 specialties
One place @DukeCancer @DukeCancerNETWK
One mission- #irAE

[Rafeh Naqash, MD, FASCO @thenasheffect]

Awesome job @afreenshariffmd @FunchainMD in bringing us all together at the Duke #ASPIRE25 meeting ! Next year to be held at @MDAndersonNews !

[Pauline Funchain @FunchainMD]

It’s a wrap for ASPirE ‘25! In medicine we continually see new challenges, face deadly obstacles, and wake up the next day to do it again. Sometimes in light. Sometimes dark. We give each other strength. Keep going fam. Keep going dear patients. Medicine perseveres. Love, ASPirE

[Lis Victoria Ravani @LisRavani]

@JCOOP_ASCO Thanks to this team: Seth Wander @maryam_lustberg @LauraTe96206949 @renata_bonadio
@MaysaVilbert @mwang_cwru Daxuan Deng

[Gabriela Gazzoni, MD @GazzoniGabriela]

Check out poster board E23 🇧🇷 at #GU25 @ASCO

We evaluated the incidence of skin reaction in EV mono in clinical trials and real-world data

📊 Incidence rate of all-grade skin reactions was 50% and about 10% in grade 3 or higher

@MaysaVilbert @isabfmichelon @anacardosomd

[Isabella Michelon @isabfmichelon]

New in Cancer Treatment Reviews!
This updated meta-analysis continues to support the activity of T-DXd in patients with CNS involvement from HER2-positive #breastcancer.
@LudiCa19862 @MaysaVilbert @AnwaarSaeed3

🔗https://t.co/S4mLPRWZVj

[Pauline Funchain @FunchainMD]

Top of the irAE to you this Monday! 2 ASPirE events to kick off 2025:

ASPirE Annual Meeting 2/28 - 3/1: in person think tank graciously hosted by @afreenshariffmd @dukemedicine

ASPirE Webinar 3/10: Launch of our Tumor Board series hosted by Yinghong Mimi Wang @MDAndersonNews

[Meta Analysis Academy @metaacademy_ofc]

From Rio de Janeiro to Boston, Cardiff to Kaliningrad, Recife to Madrid – this publication is a testament to the global connections made possible by the #metamasters.

Yasmin Mesquita led a study published in the prestigious ‘Journal of the European Academy of Dermatology and Venereology’. Her analysis of nine studies highlighted confocal microscopy as a viable alternative to histopathology in #melanoma margin mapping.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://t.co/tiiAeZ2E5m
✍️@MaysaVilbert @PTarantinoMD @E_de_Azambuja @LudiCa19862 #ADCs #HER2low

[Maysa Vilbert @MaysaVilbert]

@Cilomarf @BIDMC_HOFellows Fantastic Match!! Congratulations! Very happy for you! 👏👏🤩🤩🥳

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative therapy! TILs have the potential to CURE- complete responders from @theNCI with 10 year melanoma-specific survival of 96%. Unmodified TILs are just a starting point. Now, how do get MORE of our patients to a CR? #ImmunotherapyBridge24

[JCO Precision Oncology @JCOPO_ASCO]

Safety and Efficacy of Osimertinib in Patients With NSCLC and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. https://t.co/taHeJNM4bp @thenasheffect #LungCancer #NSCLC

[Maysa Vilbert @MaysaVilbert]

@DVAraujoMD @JCOGO_ASCO Congrats to @DVAraujoMD and this great team! Very important work!

[Daniel V. Araujo @DVAraujoMD]

1/ I’m thrilled to share our study, “Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,” now published in @JCOGO_ASCO !

🔗 https://t.co/rgJeQmjqUU

This study reflects the dedication and teamwork of everyone involved.

[Jonathan N. Priantti @jpriantti]

So proud to share our work in @JCOPO_ASCO
🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients with #NSCLC and uncommon #EGFR mutations. I’m really glad and honored to have this amazing international collaboration with this dream team.

[Maysa Vilbert @MaysaVilbert]

Congratulations @isabfmichelon and @m_dacoregio_!👏 These findings are important in understanding the impact of ADCs in #HER2-low #MBC. Honored to be part of it! Kudos to all the amazing collaborators and mentors @LudiCa19862,@jpriantti,@LucasVian2, @PTarantinoMD, @E_de_Azambuja

[Isabella Michelon @isabfmichelon]

Proud to share our work in @TAMedOncol!
Our meta-analysis of 2000+ patients with #HER2-low #MBC reveals a 50% reduction in the risk of progression/death with ADCs compared to chemo.

#BCSM
🔗 full: https://t.co/Cl4MssJIv6